Clinical Trials Logo
  1. Home
  2. Pancreatic Ductal Adenocarcinoma
  3. NCT03820661
  4. Details
NCT03820661 Clinical Trial

High Resolution Ultrasound in Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:
Advancing The Local Staging Of Pancreatic Ductal Adenocarcinoma Through High-Resolution Ultrasound: A Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03820661
Other study ID # 18-5982
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2019
Est. completion date December 2022

Study information
Verified date April 2022
Source University Health Network, Toronto
Contact Stephanie Ramotar
Phone 416-946-4501
Email Stephanie.Ramotar@uhn.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pancreatic cancer patients at UHN who have had a CT at UHN and have surgery planned will undergo a high resolution ultrasound pre-operatively and intra-operatively. This study is being done to see if using high resolution ultrasound before and during surgery will help the doctors accurately diagnose pancreatic ductal adenocarcinoma and identify if the disease has spread to other areas of the body.

Recruitment information / eligibility
Status Recruiting
Enrollment 30
Est. completion date December 2022
Est. primary completion date November 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males and females > 18 y 2. PDAC diagnosed by typical imaging findings or pathology 3. Scheduled for surgical resection 4. Contrast enhanced CT scan performed locally at UHN Exclusion Criteria: 1) Inability or unwillingness to provide informed consent

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Ultrasound
High resolution ultrasound pre-operatively and intra-operatively

Locations
Country Name City State
Canada University Health Network Toronto Ontario

Sponsors (1)
Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome
Type Measure Description Time frame Safety issue
Primary High-resolution U/S will be used to measure vascular invasion and regional lymph node metastases in PDAC The U/S results will be compared to pre-operative CT scan to help determine the diagnostic effectiveness of High Resolution US within 2 weeks of surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05209074 - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT04969731 - Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer Phase 3
Recruiting NCT05048524 - Peri-operative SLOG for Localized Pancreatic Cancer Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Completed NCT03257150 - A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer N/A
Terminated NCT04400903 - Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
Active, not recruiting NCT05462717 - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1
Active, not recruiting NCT03267316 - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Phase 1/Phase 2
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Terminated NCT04046887 - Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) Phase 1
Recruiting NCT05964621 - Venous Thromboembolism in Primary Pancreatic Tumour Resection
Active, not recruiting NCT04827953 - Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04291651 - UCSF PANC Cyst Registry
Recruiting NCT05977322 - A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Active, not recruiting NCT04862260 - Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma Early Phase 1
Active, not recruiting NCT04853017 - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Phase 1
Completed NCT03770117 - Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
Completed NCT02259114 - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Phase 1